

1 *Original research*

2

3 **New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors**  
4 **versus dipeptidyl peptidase-4 inhibitors: A Chinese population-based cohort study**

5

6 Xinyi Gao<sup>#1</sup>, Nan Zhang<sup>#1</sup>, Lei Lu<sup>2</sup>, Tianyu Gao<sup>3</sup>, Oscar Hou In Chou<sup>4</sup>, Wing Tak Wong<sup>5</sup>, Carlin  
7 Chang<sup>6</sup>, Abraham Ka Chung Wai<sup>7</sup>, Gregory Y. H. Lip<sup>8,9</sup>, Qingpeng Zhang<sup>10</sup>, Gary Tse<sup>1,11\*</sup>, Tong Liu  
8 <sup>1\*</sup>, Jiandong Zhou<sup>12\*</sup>

9

10 <sup>1</sup> Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of  
11 Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin  
12 China

13 <sup>2</sup> Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford,  
14 Oxford, United Kingdom

15 <sup>3</sup> School of Physical Education, Jinan University, Guangzhou, China

16 <sup>4</sup> Division of Clinical Pharmacology, Department of Medicine, School of Clinical Medicine, Li Ka Shing  
17 Faculty of Medicine, University of Hong Kong, Hong Kong, China

18 <sup>5</sup> School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China

19 <sup>6</sup> Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong, China

20 <sup>7</sup> Emergency Medicine Unit, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong  
21 Kong, China

22 <sup>8</sup> Liverpool Centre for Cardiovascular Sciences at University of Liverpool, Liverpool John Moores  
23 University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

24 <sup>9</sup> Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

25 <sup>10</sup> School of Data Science, City University of Hong Kong, Kowloon City, Hong Kong, China

26 <sup>11</sup> Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, and the Musketeers  
27 Foundation Institute of Data Science, University of Hong Kong, Hong Kong, China

28 <sup>12</sup> Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

29

30 # Co-first authors /equal contributions

31 \* Co-corresponding authors

32

33 **Word Count:** 4350 (excluding abstract, references, figure legends and tables)

34

35 **\* Correspondence to:**

36 Jiandong Zhou, Ph.D.,

37 Nuffield Department of Medicine, University of Oxford, Oxford, UK.

38 Email: [jiandong.zhou@ndm.ox.ac.uk](mailto:jiandong.zhou@ndm.ox.ac.uk)

39

1 Tong Liu, MD, Ph.D.,  
2 Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of  
3 Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin  
4 China. Email: [liutongdoc@126.com](mailto:liutongdoc@126.com)

5

6 Gary Tse, MD, Ph.D.,  
7 Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of  
8 Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin  
9 China. Email: [garytse86@gmail.com](mailto:garytse86@gmail.com)

## 1 **Abstract**

### 2 **Background and Aims**

3 Syncope and post-syncope adverse events lead to a heavy burden in the healthcare systems with  
4 negative impact on the economy globally. However, no effective treatments have been identified to  
5 prevent the risk of new-onset syncope. This study compared the preventive effect of incident  
6 syncope between sodium-glucose cotransporter-2 inhibitor (SGLT2i) and dipeptidyl peptidase-4  
7 inhibitor (DPP4i).

### 8 **Methods**

9 This was a retrospective, territory-wide cohort study enrolling type 2 diabetes mellitus (T2DM)  
10 patients treated with SGLT2i or DPP4i between January 1st, 2016, and December 31st, 2020, in  
11 Hong Kong, China. The outcomes were new-onset syncope, cardiovascular mortality, and all-cause  
12 mortality. Multivariable Cox regression and different approaches using the propensity score were  
13 used to evaluate the association between SGLT2i vs. DPP4i with incident syncope and mortality.

### 14 **Results**

15 After matching, a total of 37502 patients with T2DM were included (18751 SGLT2i users, 18751  
16 DPP4i users). During a median follow-up of 5.56 years, compared to DPP4i users, SGLT2i therapy  
17 was associated with a 51% lower risk of new-onset syncope (HR, 0.49; 95%CI [0.41-0.57],  $P<0.001$ ),  
18 65% lower risk of cardiovascular mortality (HR, 0.35; 95%CI [0.26-0.46],  $P<0.001$ ), and a 70% lower  
19 risk of all-cause mortality (HR, 0.30; 95%CI [0.26-0.34],  $P<0.001$ ) in the fully adjusted model. Similar  
20 association with syncope was observed for dapagliflozin (HR, 0.70; 95%CI [0.58-0.85],  $P<0.001$ ),  
21 canagliflozin (HR, 0.48; 95%CI [0.36-0.63],  $P<0.001$ ) and ertugliflozin (HR, 0.45; 95%CI [0.30-0.68],  
22  $P<0.001$ ), but was attenuated for empagliflozin (HR, 0.79; 95%CI [0.59-1.05],  $P=0.100$ ) after  
23 adjusting for potential confounders. Subgroup analyses suggested that, compared to DPP4i, SGLT2i  
24 showed a significantly protective effect in incident syncope among T2DM patients, regardless of  
25 gender, age, comorbidities burden and other medication history, as well as among patients with  
26 different levels of fasting glucose, HbA1c, and glycemic variability.

1 **Conclusions**

2 Compared to DPP4i, SGLT2i could significantly reduce the risk of new-onset syncope in patients  
3 with T2DM, regardless of gender, age, comorbidities, other medication history, and degree of  
4 glycemic control. Our findings suggest a promising future of SGLT2i in preventing incident syncope.

5

6 **Keywords** Sodium-glucose cotransporter-2 inhibitor; Dipeptidyl peptidase-4 inhibitor; Diabetes  
7 mellitus; Syncope; Cardiovascular mortality; All-cause mortality

## 1 Introduction

2 Syncope is defined as a condition of transient loss of consciousness due to global cerebral  
3 hypo-perfusion and characterized by rapid, self-limiting onset and complete recovery. It is a  
4 common problem that affects all age groups, which accounts for 1-3% of emergency department  
5 visits and 6% of hospitalizations, with a lifetime cumulative incidence up to 40% [1, 2]. Syncope  
6 serves as a common presentation of a number of clinical conditions ranging from benign to  
7 life-threatening diseases, and its causes are difficult to diagnose [3]. Consequently, it often results  
8 in unnecessary hospital admissions, multiple consultations, and the performance of many  
9 diagnostic tests, which poses a substantial economic burden [4]. Beyond the economic impact,  
10 syncope is associated with impaired quality of life, significant morbidity and mortality [5]. It has  
11 been reported that the mortality rate is 6.9% and 25.2% at 10 days and 2 years after syncope,  
12 respectively [6]. Therefore, it is of the utmost importance to develop some novel agents to prevent  
13 incident syncope or to identify the syncope-prevention effect of some old classic drugs, in order to  
14 reduce the burden of syncope. However, to our knowledge, management of syncope remains  
15 challenging and the field of pharmacologic prevention of incident syncope is still blank until now.

16 Diabetes represents an important risk factor for syncope, which has been associated with a  
17 higher recurrence rate [7, 8]. The latest class of anti-diabetic agent, sodium-glucose cotransporter-2  
18 inhibitor (SGLT2i), have received significant attention owing to their beneficial effects on  
19 cardiovascular events, especially in the context of heart failure [9-15]. Interestingly, a recent study  
20 which included 324 patients with type 2 diabetes mellitus (T2DM) and vasovagal syncope (VVS),  
21 reported that SGLT2i could significantly reduce the risk of VVS recurrence during 1-year follow-up,  
22 compared to non-SGLT2i anti-diabetic agents [16]. Meanwhile, another novel class of hypoglycemic  
23 agent, the dipeptidyl peptidase-4 inhibitor (DPP4i), has been associated with favorable or neutral  
24 cardioprotective effects than non-users [17-20]. SGLT2i and DPP4i represent two promising  
25 anti-diabetic agents, both of them are widely used oral preparations in clinical practice. However,  
26 no study has investigated the effects of SGLT2i and DPP4i in preventing the new-onset syncope.  
27 Therefore, this study used a population-based cohort to compare the prophylactic effects of SGLT2i

1 vs. DPP4i on new-onset syncope, and to explore the subsets of patients who may benefit more  
2 from these treatments.

### 3 **Method**

#### 4 **Study Design and Population**

5 This study was granted approval by the Institutional Review Board of the University of Hong  
6 Kong/Hospital Authority Hong Kong West Cluster and The Joint Chinese University of Hong  
7 Kong–New Territories East Cluster Clinical Research Ethics Committee. This was a retrospective,  
8 territory-wide cohort study of T2DM patients on either SGLT2i or DPP4i with the first index  
9 prescription date between January 1<sup>st</sup>, 2016, and December 31<sup>st</sup>, 2020, in Hong Kong.

10 Patients of this study have been identified from the Clinical Data Analysis and Reporting System  
11 (CDARS), which centralizes information on patients from individual local hospitals to establish  
12 comprehensive medical data throughout the Hong Kong. The system has been previously utilized by  
13 multiple teams to conduct population-based cohort studies [21-24], including those focused on  
14 diabetes [25]. All pertinent data including clinical characteristics, disease diagnoses, laboratory  
15 results and drug treatment details based on the population in Hong Kong can be extracted from this  
16 system. In the current study, patients aged 18 years and older with T2DM who were prescribed and  
17 regularly taken SGLT2i (dapagliflozin, canagliflozin, empagliflozin, or ertugliflozin) or DPP4i  
18 (vildagliptin, sitagliptin, saxagliptin, alogliptin, or linagliptin) during the indicated period were  
19 enrolled and followed up until death or December 31, 2020. Patients were excluded if one of the  
20 following criteria was met: 1) received both SGLT2i and DPP4i; 2) had exposed to SGLT2i or DPP4i  
21 less than 1 month; 3) with prior diagnosis of ventricular tachycardia, ventricular fibrillation, sudden  
22 cardiac death, congenital long QT syndrome or syncope before the initial drug exposure.

#### 23 **Data collection**

24 All extracted covariates of interest were displayed in **Table 1** for confounder adjustment, including  
25 patient demographic characteristics i.e., gender and age at initiation of SGLT2i/DPP4i, prior  
26 comorbidities, Charlson's standard comorbidity index, frequency and duration of SGLT2i/DPP4i

1 exposure, and other medication histories. Baseline laboratory data, including complete blood count,  
2 indicators of liver and kidney function, lipid and glucose profiles were also extracted. Prior  
3 comorbidities were documented in CDARS under the International Classification of Diseases Ninth  
4 Revision (ICD-9) codes (**Table S1**), as CDARS has not implemented the International Classification of  
5 Diseases Tenth Revision (ICD-10) codes for disease diagnoses to date [26, 27].

## 6 **Outcomes**

7 The primary outcome of this study was hospitalization for new-onset syncope, which was identified  
8 from the CDARS using the ICD-9 code 780.2 “syncope and collapse”. Secondary outcome were  
9 cardiovascular mortality and all-cause mortality. Cardiovascular mortality was identified by ICD-10  
10 codes: I00-I09, I11, I13, and I20-I51. The mortality data was documented in the Hong Kong Death  
11 Registry, a population-based official government registry with the registered death records of all  
12 Hong Kong citizens linked to CDARS under ICD-10 codes [28].

## 13 **Statistical Analysis**

14 Baseline characteristics of patients treated with SGLT2i and DPP4i was summarized using  
15 descriptive statistics. Continuous variables were presented as median [95% confidence interval (CI)/  
16 interquartile range] or mean [standard deviation (SD)] and categorical variables was presented as  
17 total number (percentage). Continuous variables were compared using the two-tailed  
18 Mann–Whitney U test, whilst the two-tailed  $\chi^2$  test with Yates’ correction was used to test 2 × 2  
19 contingency data.

20 Propensity score matching (PSM) was used to generate SGLT2i and DPP4i cohorts in a 1:1 ratio  
21 using the nearest neighbour matching strategy. All of the variables extracted that may influence  
22 treatment selection and outcomes of interest including demographic characteristics, comorbidities,  
23 non-SGLT2i/DPP4i drugs, and biochemical indicators were incorporated. Variable selection was  
24 based on clinical reasoning, not statistical significance [29]. Baseline and clinical characteristics of  
25 patients with/without new-onset syncope were compared before and after PSM using standardised  
26 mean differences (SMD). Univariable Cox models were used to identify significant risk factors for

1 the outcomes. Further, multivariate Cox regression analyses were sequentially fitted with 5 models  
2 to fully estimate the adjusted hazard ratio (HR) and 95% CI for the outcomes.

3 Subgroup analyses were conducted according to age (<65 and >65 years), gender, Charlson's  
4 comorbidity index, individual comorbidities, medication history, and a spectrum of glucose  
5 measurements, including baseline and mean levels of HbA1c and fasting glucose, as well as  
6 glycemic variability assessed by derivation of variance and coefficient of variation (CV). Mean levels  
7 of HbA1c and fasting glucose were calculated based on the collected tests before initial drug  
8 exposure. The glycemic variability are calculated based on at least three measurements of HbA1c  
9 and fasting glucose [30].

10 To test the robustness of our results, different sensitivity analyses were performed. First,  
11 alternative propensity score approaches, including propensity score stratification, inverse  
12 probability of treatment weighting (IPTW) and stable inverse probability of treatment weighting  
13 (SIPTW), as well as competing risk analyses using cause-specific and sub-distribution hazard models  
14 were conducted [31-33]. Second, patients with baseline immune-mediated inflammation and  
15 cancer which might affect the outcomes were excluded. Third, patients with chronic kidney disease  
16 (CKD) stage 4/5 (estimated glomerular filtration rate <30 ml/min/1.73 m<sup>2</sup>), peritoneal dialysis or  
17 hemodialysis at baseline were excluded to further validate our results. Fourth, a 1-year lag time  
18 approach was applied, which could improve drug-outcome association estimates in presence of  
19 protopathic bias and minimize time-lag effect of treatment [34]. Besides, marginal effects analyses  
20 were performed to explore whether the relationship between SGLT2i/DPP4i exposure and syncope  
21 was modulated by other variables [35].

22 Negligible post-weighting inter-group standardized mean difference was defined as an SMD <  
23 0.2 [21]. The HR, 95% CI and P value will be reported. P value <0.05 is considered statistically  
24 significant. The statistical analysis was performed with RStudio software (Version 1.1.456) and  
25 Python (Version 3.6).

26

27 **Results**



## 1 **Baseline characteristics**

2 A total of 76147 T2DM patients treated with SGLT2i or DPP4i were identified between January 1,  
3 2015 and December 31, 2020. After exclusion, 55370 patients (50.48% males; mean age, 63.2 years)  
4 were enrolled, including 18751 (33.86%) SGLT2i users and 36619 (66.14%) DPP4i users. Of the  
5 18751 SGLT2i users, 10549 were treated with dapagliflozin (56.25%), 3913 with empagliflozin  
6 (20.86%), 4998 with canagliflozin (26.65%) and 2509 with ertugliflozin (13.38%). Over a median  
7 follow-up of 5.56 (5.24, 5.80) years, 1374 patients were hospitalized for new-onset syncope  
8 [incidence rate (IR), 2.48%], and 6000 patients died from any cause (IR: 10.83%), among which 1762  
9 deaths (IR: 3.18%) were associated with cardiovascular causes (**Figure 1**).

10 After PSM, majority of baseline characteristics between SGLT2i users and DPP4i users were  
11 balanced, with the exception of overall age and SD of high-density lipoprotein (SMD > 0.2), and  
12 37502 individuals were analyzed (53.31% males; median age, 58.9 years) (**Table 1** and **Figure S1**).  
13 Baseline characteristics of the included patients according to the occurrence of syncope before and  
14 after 1:1 PSM are presented in **Table S2**.

## 15 **The association between SGLT2i vs. DPP4i and incident syncope**

16 During a median follow-up of 5.56 years, a significantly lower cumulative event rate of new-onset  
17 syncope was observed in patients treated with SGLT2i, in relation to DPP4i users (**Figure 2**). The  
18 annual person-year incidence ratios of incident syncope in the matched cohort are summarized in  
19 **Figure S2** and **Table S3**, patients treated with SGLT2i had smaller person-year incidence ratio in  
20 each year of follow-up duration than those with DPP4i exposure. In univariable Cox regression,  
21 SGLT2i therapy was associated with a significantly lower risk of new-onset syncope (HR, 0.43; 95%CI  
22 [0.37-0.49],  $P < 0.001$ ) (**Table S4**). The results remained stable after adjusting for potential  
23 confounders and were consistent across five models (**Table 2**). In the fully adjusted model (Model  
24 5), SGLT2i users presented with an over 50% lower risk of new-onset syncope (HR, 0.49; 95%CI  
25 [0.41-0.57],  $P < 0.001$ ) than the DPP4i users.

26 Amongst different SGLT2i, dapagliflozin (HR, 0.70; 95%CI [0.58-0.85],  $P < 0.001$ ), canagliflozin  
27 (HR, 0.48; 95%CI [0.36-0.63],  $P < 0.001$ ) and ertugliflozin (HR, 0.45; 95%CI [0.30-0.68],  $P < 0.001$ ) were

1 associated with significantly lower risks of new-onset syncope. Whereas the preventive effect of  
2 empagliflozin on incident syncope was attenuated after adjusting for potential confounders (HR,  
3 0.79; 95%CI [0.59-1.05], P=0.100) (**Table 2**).

#### 4 **Results of subgroup analyses**

##### 5 **Subgroup analysis according to gender and age**

6 In subgroup analysis according to gender, compared to DPP4i users, both the female (HR, 0.54;  
7 95%CI [0.42-0.70], P<0.001) and male (HR, 0.66; 95%CI [0.55-0.80], P<0.001) SGLT2i users  
8 experienced a significantly lower risk of new-onset syncope. In addition, compare to male SGLT2i  
9 users, female patients treated with SGLT2i showed a more prominently decreased risk of syncope,  
10 which suggested that both female and male patients could benefit from SGLT2i therapy in  
11 preventing incident syncope, whereas female patients might benefit more than male (**Figure S3**). In  
12 subgroup analysis according to age, both the younger (<65 years, HR, 0.59; 95%CI [0.47-0.73],  
13 P<0.001) and older (>65 years, HR, 0.71; 95%CI [0.58-0.87], P=0.001) SGLT2i users showed a  
14 significantly reduced risk of syncope than DPP4i users (**Figure S3**). Amongst the SGLT2i users,  
15 younger patients showed a more prominently lower risk of new-onset syncope than the older  
16 patients (**Figure 3**).

##### 17 **Subgroup analyses according to glucose measurements**

18 To investigate the effects of different glucose control status on the association between SGLT2i vs.  
19 DPP4i and syncope, subgroup analyses according to a spectrum of glucose measurements, including  
20 baseline and mean level, as well as variability of HbA1c and fasting glucose, were conducted (**Table**  
21 **3**). Compared with DPP4i, SGLT2i treatment could significantly reduce the incidence of new-onset  
22 syncope in patients with different levels of baseline HbA1c (less than 7.5%, between 7.5% and 9%,  
23 and greater than 9%), as well as in different quartile subgroups of mean HbA1c, and variance/CV of  
24 HbA1c. We also observed such protection effects of individual SGLT2i treatments including  
25 dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin, in most of the subgroups. Similar  
26 findings of the protection effects of SGLT2i vs. DPP4i were obtained in subgroups of fasting glucose.

## 1 **Subgroup analyses according to comorbidities and medication history**

2 In addition, we observed a consistently protective effect of SGLT2i in preventing future syncope  
3 occurrence among T2DM patients with different levels of Charlson's comorbidity index (from 0 to  
4 5+), compared to DPP4i (**Table S5**). However, there was also a signal that patients with lower  
5 Charlson's comorbidity index might benefit more from individual SGLT2i treatment than those with  
6 higher comorbidity burden. Further analyses according to individual comorbidities were performed  
7 (**Table S6**). Compared to DPP4i, SGLT2i could significantly reduce the risk of incident syncope in  
8 T2DM patients complicated with cancer (HR, 0.18; 95%CI [0.06-0.53], P=0.002), hypertension (HR,  
9 0.54; 95%CI [0.43-0.69], P<0.001), non-acute myocardial infarction ischemic heart disease (IHD) (HR,  
10 0.43; 95%CI [0.30-0.60], P<0.001), stroke/transient ischemic attack (TIA) (HR, 0.55; 95%CI  
11 [0.32-0.96], P=0.036), liver diseases (HR, 0.41; 95%CI [0.21-0.79], P=0.008), and renal diseases (HR,  
12 0.12; 95%CI [0.02-0.96], P=0.046), but not significant among those complicated with other  
13 comorbidities listed in this study (**Figure 3**).

14 Furthermore, compare to DPP4i, SGLT2i presented a favorable effect on preventing incident  
15 syncope, regardless of baseline medication history of antihypertensive drugs (such as  
16 angiotensin-converting enzyme inhibitor [ACEI]/angiotensin receptor blocker [ARB], beta-blockers,  
17 calcium channel blockers, and diuretics), antiplatelet drugs, lipid-lowering drugs (statins and  
18 fibrates), and most antidiabetic drugs (such as metformin, sulphonylurea, and insulin) (**Figure 3** and  
19 **Table S7**).

## 20 **Results of sensitivity analyses and marginal effects analysis**

21 Results from several sensitivity analyses are in agreement with the primary analysis. Compared to  
22 DPP4i, SGLT2i therapies were associated with significantly decreased risk of new-onset syncope  
23 when using alternative propensity score approaches, including propensity score stratification (HR,  
24 0.32; 95%CI [0.25-0.53], P<0.001), IPTW (HR, 0.39; 95%CI [0.34-0.45], P<0.001), and SIPTW (HR,  
25 0.49; 95%CI [0.42-0.63], P<0.001) or applying cause-specific (HR, 0.29; 95%CI [0.21-0.35], P<0.001)  
26 and sub-distribution hazard model (HR, 0.35; 95%CI [0.28-0.52], P<0.001) (**Table S8**). The  
27 association between SGLT2i and reduced syncope risk was stable when excluding patients with

1 baseline immune-mediated inflammatory diseases and cancer (HR, 0.42; 95%CI [0.37-0.62], P  
2 <0.001) (**Table S9**), or applying 1-year lag time approach (HR, 0.43; 95%CI [0.37-0.49], P<0.001)  
3 (**Table S10**). In addition, after excluding patients with stage 4/5 CKD, peritoneal dialysis or  
4 haemodialysis, both the overall SGLT2is (HR, 0.47; 95%CI [0.41-0.55], P<0.001) and four individual  
5 SGLT2i, including empagliflozin (HR, 0.70; 95%CI [0.53-0.91], P=0.009) showed a significantly  
6 superior protective effect on incident syncope than DPP4i (**Table S11**).

7 To further clarify whether the relationship between SGLT2i/DPP4i exposure and syncope was  
8 modulated by other variables, marginal effects analyses were performed. The results demonstrated  
9 a superiorly protective effect of SGLT2i than DPP4i on incident syncope, regardless of the age at  
10 initial drug exposure, baseline Charlson's index, number of previous hospitalizations, duration of  
11 T2DM, and number of prior anti-diabetic drugs (**Figure S4**).

## 12 **The association between SGLT2i vs DPP4i and death outcomes**

13 Apart from syncope, SGLT2i also showed a significantly protective effect on cardiovascular mortality  
14 and all-cause mortality, compared to DPP4i (**Figure S5**). In the fully adjusted model, patients treated  
15 with SGLT2i showed a 65% and 70% reduced risk of cardiovascular mortality (HR, 0.35; 95%CI  
16 [0.26-0.46], P<0.001) and all-cause mortality (HR, 0.30; 95%CI [0.26-0.34], P<0.001), compared to  
17 DPP4i (**Table 2**). The results of the subgroup analyses and sensitivity analyses regarding the  
18 association between SGLT2i vs. DPP4i with mortality were in line with the primary analysis (**Figure**  
19 **S6-7** and **Table S8** and **Table S10-14**).

20

## 21 **Discussion**

22 In this population-based cohort study, several key findings were noted. First, SGLT2i treatment was  
23 associated with significantly lower risk of new-onset syncope, cardiovascular mortality and all-cause  
24 mortality compared to DPP4i therapy, especially for dapagliflozin, canagliflozin and ertugliflozin,  
25 which were consistent across different models and through comprehensive sensitivity analyses.  
26 Second, compared to DPP4i, SGLT2i showed a significantly protective effect on incident syncope,

1 regardless of gender and age, whereas female and younger patients might benefit more than male  
2 and older patients, respectively. Third, compared with DPP4i, SGLT2i treatment could significantly  
3 reduce the risk of new-onset syncope among T2DM patients with different levels of baseline and  
4 mean HbA1c and fasting glucose, and various degree of glycemic variability. Fourth, SGLT2i showed  
5 a significantly favorable effect on preventing incident syncope, regardless of comorbidities burden  
6 and other medication use.

7 To our knowledge, there was only one previous study focusing on anti-diabetic agents and  
8 syncope [16]. The SCAN study has included 324 T2DM patients with VVS (161 SGLT2i users and 163  
9 non-SGLT2i users), and observed that SGLT2i significantly reduced the risk of VVS recurrence during  
10 1-year follow-up compared to non-SGLT2i treatments [16]. However, the SCAN study only included  
11 patients with VVS and focused on the recurrent but not incident risk of syncope. Compared to the  
12 previous study, our study has several strengths. First, our study is a large-scale, population-based  
13 cohort including 55370 T2DM patients, and with a relatively long-term follow-up duration (5.56  
14 years), which could provide reliable estimation of the association between SGLT2i and syncope.  
15 Second, instead of investigating the recurrence risk, our study has focused on the risk of new-onset  
16 syncope, which has never been addressed before and could provide some novel insights into the  
17 prevention strategy of syncope. Third, DPP4i has been widely used in clinical practice and  
18 associated with favorable or neutral cardioprotective effects [17-20], which has been used as  
19 comparator in numerous large-scale studies focusing on the effects of SGLT2i in various clinical  
20 outcomes [17, 36]. Some studies have compared the effects between SGLT2i and glucagon-like  
21 peptide-1 receptor agonist (GLP-1RA), another promising class of antidiabetic agent, in clinical  
22 outcomes, which yield controversial results. We have also conducted an additional three-arm  
23 (SGLT2i vs. DPP4i vs. GLP-1RA) as-treat analysis presented in Table S15, which observed a favorable  
24 signal for SGLT2i in preventing syncope than GLP-1RA, whereas the difference did not reach the  
25 traditional significance (HR, 0.89; 95%CI [0.66-1.19], P=0.382). However, the sample size of the  
26 GLP-1RA arm in our database is relatively small, which may introduce selection bias. Therefore,  
27 using DPP4i as comparator in our study could guarantee the reliability of our results and also  
28 facilitate choosing appropriate preventive therapeutic options. In addition, different from the SCAN

1 study [16], our primary outcome was anchored on overall syncope rather than on a specific type of  
2 syncope classification. The accurate etiology of syncope is hard to identify in real-world settings,  
3 with up to 42.1% patients having the possibility to be diagnosed with unknown-cause of syncope  
4 and a considerable portion of patient with misclassified causes of syncope [37]. Moreover, the  
5 accuracy rate of head-up tilt test, which could facilitate the diagnosis of reflex syncope, is only  
6 about 60% [38, 39]. Therefore, it is appropriate to focus on the overall syncope population,  
7 especially when there lacks a golden standard to accurately identify the etiology of syncope.

8 Another finding of this study is that empagliflozin is the only SGLT2i of the 4 studied that failed  
9 to reach statistical significance on incident syncope in the fully adjusted model, whereas the  
10 association between other three SGLT2i and syncope existed across five models, which might  
11 suggests a more prominently protective effect of dapagliflozin, canagliflozin and ertugliflozin on  
12 incident syncope. Interestingly, it should be noticed that after applying 1-year lag time approach or  
13 excluding patients with stage 4/5 CKD, peritoneal dialysis or haemodialysis, all of these four SGLT2is  
14 (including empagliflozin) showed significantly favorable effects on preventing syncope. Some  
15 previous studies have also observed a difference in pharmacologic effects on various outcomes  
16 between individual SGLT2i [9, 40, 41]. The mechanism underlying the observed heterogeneity  
17 between different SGLT2i and syncope remains unclear, which might be due to the difference in  
18 SGLT2 selectivity [42] and other non-SGLT2 mediated mechanisms [43]. For instance, prior study  
19 has demonstrated off-target effects of SGLT2i, including the direct effect on the sodium-hydrogen  
20 exchanger 1 (NHE1) in the heart, NHE3 in the kidney, and NHE9 in inflammatory cells that could  
21 impact cardiac and kidney outcomes [44]. Hence, further investigation into the potential  
22 mechanisms of such observations and to what degree these effects differ between members of the  
23 class is of utmost importance.

24 Moreover, our findings suggest that extensive groups of individuals could benefit from SGLT2i  
25 therapy in reducing incident syncope, which possess important clinical implications and has the  
26 potential to improve syncope preventive strategy. First, SGLT2i is superior to DPP4i in reducing the  
27 risk of new-onset syncope among patients with T2DM, regardless of gender and age. Whereas  
28 compared to male, female SGLT2i users have a lower incidence rate of syncope, which might

1 suggest a more beneficial role of SGLT2i in female population than male in the syncope settings.  
2 Our study also observed that younger SGLT2i users have a lower risk of incident syncope than older  
3 users, which may be, at least partially, attributed to the multimorbidity, aging and frailty of the  
4 older populations [45]. However, this observation may also imply that younger patients could  
5 benefit more from SGLT2i treatment in preventing syncope than the older patients, and that  
6 remains to be further investigated. Second, SGLT2i could lower the risk of incident syncope among  
7 T2DM patients with varying degrees of glycemic control, namely among patients with different  
8 levels of fasting glucose, HbA1c, and glycemic variability. Third, SGLT2i therapy prevents incident  
9 syncope in patients with T2DM, regardless of comorbidities burden (Charlson's comorbidity index  
10 from 0 to 5+). More specifically, SGLT2i could reduce the risk of new-onset syncope among T2DM  
11 patients complicated with hypertension, IHD, renal diseases, or stroke/TIA, which have been  
12 demonstrated as risk factors for syncope [8]. Fourth, it has been reported that individuals using  
13 cardiac medications were at increased risk for syncope [8]. Our finding suggests that SGLT2i  
14 significantly reduces the risk of syncope among T2DM patients, regardless of medication history,  
15 such as antihypertensive drugs (ACEI/ARB, beta-blockers, calcium channel blockers, and diuretics),  
16 antiplatelet drugs, lipid-lowering drugs, and other antidiabetic drugs. Therefore, SGLT2i holds a  
17 promising future in preventing incident syncope.

18 The underlying mechanisms of the favorable effects of SGLT2i on syncope remains unclear.  
19 Based on the current researches, several hypotheses may help explain the observed associations.  
20 First, the favorable glycemic lowering effect of SGLT2i can slow down the progression of cardiac  
21 autonomic dysfunction (CAN) and therefore reduce the occurrence of VVS [16, 46, 47]. Second,  
22 independently of the hypoglycemic effect, SGLT2i may have the potential to directly improve or  
23 reverse CAN, thereby reducing the incidence of syncope [16]. Third, the protective role of SGLT2i in  
24 preventing syncope may be partially mediated by the favorable effects of SGLT2i in cardiovascular  
25 outcomes, such as heart failure, atherosclerotic cardiovascular diseases, atrial fibrillation and  
26 related thromboembolic events [36, 48-50]. Fourth, a poor kidney function has been associate with  
27 a higher risk of syncope [51]. Therefore, the established renoprotective effects of SGLT2i may also

1 contribute to the favorable effect on syncope. In addition, future investigations are needed to  
2 explore the direct effects of SGLT2i on syncope.

### 3 **Study limitations**

4 Several limitations should be noted for the present study. First, given the inherited nature of  
5 retrospective study, information bias from under-coding and coding errors are possible. However,  
6 the outcomes from the CDARS receive validation from review of medical records by physicians who  
7 have been responsible for the care of the patients, which could reduce the possibility of miscoding.  
8 And given the large sample size of this study, missing of a few syncope cases without hospitalization  
9 seems unlikely to significantly affect the primary results. Second, the lack of randomization cannot  
10 be fully replaced by propensity score matching. Indeed, it should be acknowledged that it is not  
11 always feasible to conduct an randomized clinical trial, such as in population with syncope, among  
12 which the underlying cause is often difficult to identify. Additionally, to testify our results, we have  
13 applied four PSM approaches and conducted comprehensive sensitivity analyses, which have  
14 yielded similar results. Third, out-of-hospital syncope was not included as an outcome event  
15 because the outcome was extracted exclusively from the medical record database. Fourth, our  
16 study only included four types of SGLT2i approved in China, including dapagliflozin, canagliflozin,  
17 empagliflozin, and ertugliflozin, which also represent the most common used SGLT2i in most of  
18 other countries. Other novel types of SGLT2i, such as ipragliflozin, tofogliflozin, luseogliflozin and  
19 sotagliflozin, are not approved in China yet and were not included in this study. Fifth, given the  
20 ICD-codes derived outcomes, the complexity of syncope, and the fact that the etiology of syncope is  
21 hard to identify, our study was unable to detailed classify the etiology of syncope and investigate  
22 the nature of syncope, which is also a common challenge existed in other large-scale syncope  
23 researches [52, 53]. Therefore, the mechanisms of the observed benefits of SGLT2i remain  
24 speculative which requires further investigations. Sixth, due to the nature of real-word study, the  
25 choice of performing echocardiography was at the discretion of the physicians. Therefore,  
26 echocardiographic data, such as left ventricular ejection fraction, was not available in the current  
27 study.



1 **Conclusions**

2 SGLT2i therapy demonstrate robust clinical effectiveness in preventing new-onset syncope among  
3 patients with T2DM, regardless of gender, age, comorbidities, other medication history, and degree  
4 of glycemic control. Our findings suggest a promising future of SGLT2i in preventing incident  
5 syncope which have the potential to improve the preventive strategy of syncope.

6

7 **Authors contributions**

8 X.G.: wrote the research project, and wrote and edited the manuscript; N.Z.: wrote and edited the  
9 manuscript; L.L., T.G., J.Z.: prepared the figures and performed statistical analyses; G.T.: edited and  
10 revised the manuscript; W.T.W., C.C., A.K.C.W.: contributed to the discussion and reviewed the  
11 manuscript; G.Y.H.L., T.L., J.Z.: reviewed the results and revised the manuscript. All authors have  
12 read and agreed to the published version of the manuscript.

13 **Ethical approval statement**

14 This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital  
15 Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250) and complied with the  
16 Declaration of Helsinki.

17 **Declaration of competing interest**

18 G.Y.H.L. is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Anthos and  
19 Daiichi-Sankyo. No fees are directly received personally. The remaining authors have no disclosures  
20 to report.

21 **Data availability statement**

22 The datasets analysed during the current study are not publicly available as they contain personal  
23 data and the data custodians have not given permission. The data are available from the electronic  
24 health database in the computerized Clinical Management System of the Hong Kong Hospital

1 Authority, subject to an application and research proposal meeting the ethical and governance  
2 requirements.

### 3 **Code availability**

4 All analysis codes supporting the findings are available from the corresponding author upon  
5 reasonable request.

### 6 **Acknowledgments**

7 All the authors, and colleagues the Hospital Authority for providing de-identified clinical data are  
8 equally thanked for their contributions to this research. Special thanks to the support of the  
9 National Natural Science Foundation of China (81970270, 82170327 to TL) and the Tianjin Key  
10 Medical Discipline (Specialty) Construction Project (TJXZDXK-029A). Structural graphical abstract  
11 and Figure 1 are created with BioRender.com.

## 1 References

- 2 1. Alshekhlee, A., et al., *Incidence and mortality rates of syncope in the United States*. Am J Med, 2009. **122**(2): p. 181-8.
- 3 181-8.
- 4 2. Blanc, J.J., et al., *Prospective evaluation and outcome of patients admitted for syncope over a 1 year period*. Eur Heart J, 2002. **23**(10): p. 815-20.
- 5 815-20.
- 6 3. Brignole, M., et al., *2018 ESC Guidelines for the diagnosis and management of syncope*. Eur Heart J, 2018.
- 7 **39**(21): p. 1883-1948.
- 8 4. Sandhu, R.K., et al., *A Population-Based Cohort Study Evaluating Outcomes and Costs for Syncope Presentations to the Emergency Department*. JACC Clin Electrophysiol, 2018. **4**(2): p. 265-273.
- 9 265-273.
- 10 5. Saklani, P., A. Krahn, and G. Klein, *Syncope*. Circulation, 2013. **127**(12): p. 1330-9.
- 11 6. Solbiati, M., et al., *Syncope recurrence and mortality: a systematic review*. Europace, 2015. **17**(2): p. 300-8.
- 12 7. Sardu, C., et al., *Cardiac syncope recurrence in type 2 diabetes mellitus patients vs. normoglycemics patients: The CARVAS study*. Diabetes Res Clin Pract, 2019. **151**: p. 152-162.
- 13 152-162.
- 14 8. Chen, L., et al., *Risk factors for syncope in a community-based sample (the Framingham Heart Study)*. Am J Cardiol, 2000. **85**(10): p. 1189-93.
- 15 1189-93.
- 16 9. Zhang, N., et al., *Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis*. Eur J Prev Cardiol, 2022. **28**(17): p. 1961-1973.
- 17 1961-1973.
- 18 10. Inzucchi, S.E., et al., *SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials*. Diab Vasc Dis Res, 2015. **12**(2): p. 90-100.
- 19 90-100.
- 20 11. Baglioni, P., *Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes*. N Engl J Med, 2017. **377**(21): p. 2097-8.
- 21 2097-8.
- 22 12. Sfairopoulos, D., et al., *Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials*. Heart Fail Rev, 2022.
- 23 2022.
- 24 13. Bazoukis, G., et al., *Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials*. J Geriatr Cardiol, 2021. **18**(10): p. 783-795.
- 25 783-795.
- 26 14. Wiviott, S.D., et al., *Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes*. N Engl J Med, 2019. **380**(4): p. 347-357.
- 27 347-357.
- 28 15. Sfairopoulos, D., et al., *Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials*. Europace, 2022.
- 29 2022.
- 30 **24**(1): p. 20-30.
- 31 20-30.
- 32 16. Sardu, C., et al., *SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study*. Metabolism, 2022. **137**: p. 155243.
- 33 155243.
- 34 17. Fu, E.L., et al., *Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study*. Eur Heart J, 2023.
- 35 2023.
- 36 18. Bain, S., et al., *Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data*. Diabetes Obes Metab, 2017. **19**(3): p. 329-335.
- 37 329-335.
- 38 19. Farah, D., et al., *A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis*. Diabetes Res Clin Pract, 2019. **149**: p. 47-63.
- 39 47-63.
- 40 47-63.
- 41 47-63.

- 1 20. Kaneko, M. and M. Narukawa, *Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in*  
2 *patients with type 2 diabetes mellitus*. *Diabetes Res Clin Pract*, 2016. **116**: p. 171-82.
- 3 21. Zhou, J., et al., *Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity*  
4 *score-matched territory-wide study*. *Gut*, 2021. **70**(10): p. 2012-2013.
- 5 22. Ju, C., et al., *Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and*  
6 *febuxostat versus allopurinol users*. *Rheumatology (Oxford)*, 2020. **59**(9): p. 2340-2349.
- 7 23. Wong, J.Y.H., et al., *Incidence of Emergency Department Visits for Sexual Abuse Among Youth in Hong Kong*  
8 *Before and During the COVID-19 Pandemic*. *JAMA Network Open*, 2022. **5**(10): p. e2236278-e2236278.
- 9 24. Xiong, X., et al., *Impact of varying wave periods of COVID-19 on in-hospital mortality and length of stay for*  
10 *admission through emergency department: A territory-wide observational cohort study*. *Influenza and Other*  
11 *Respiratory Viruses*, 2022. **16**(2): p. 193-203.
- 12 25. Chang, C., et al., *Predictive value of neutrophil-to-lymphocyte ratio for atrial fibrillation and stroke in type 2*  
13 *diabetes mellitus: The Hong Kong Diabetes Study*. *Endocrinol Diabetes Metab*, 2022: p. e397.
- 14 26. Chan, J.S.K., et al., *Temporal trends in cardiovascular burden among patients with prostate cancer receiving*  
15 *androgen deprivation therapy: a population-based cohort study*. *Br J Cancer*, 2023. **128**(12): p. 2253-2260.
- 16 27. Zhou, J., et al., *Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl*  
17 *peptidase-4 (DPP4) inhibitors in type-2 diabetes*. *Rheumatology (Oxford)*, 2023. **62**(4): p. 1501-1510.
- 18 28. Chan, J.S.K., et al., *High visit-to-visit cholesterol variability predicts heart failure and adverse cardiovascular*  
19 *events: a population-based cohort study*. *Eur J Prev Cardiol*, 2022. **29**(14): p. e323-e325.
- 20 29. Robins, J.M., *Data, design, and background knowledge in etiologic inference*. *Epidemiology*, 2001. **12**(3): p.  
21 313-20.
- 22 30. Ceriello, A., L. Monnier, and D. Owens, *Glycaemic variability in diabetes: clinical and therapeutic implications*.  
23 *Lancet Diabetes Endocrinol*, 2019. **7**(3): p. 221-230.
- 24 31. Fine, J.P., *A proportional hazards model for the subdistribution of a competing risk*. *Journal of the American*  
25 *statistical association*. *Journal of the American statistical association*, 1999(94(446)): p. 496-509.
- 26 32. Latouche, A., et al., *A competing risks analysis should report results on all cause-specific hazards and*  
27 *cumulative incidence functions*. *J Clin Epidemiol*, 2013. **66**(6): p. 648-53.
- 28 33. Austin, P.C., et al., *Estimation of the Absolute Risk of Cardiovascular Disease and Other Events: Issues With the*  
29 *Use of Multiple Fine-Gray Subdistribution Hazard Models*. *Circ Cardiovasc Qual Outcomes*, 2022. **15**(2): p.  
30 e008368.
- 31 34. Arfe, A. and G. Corrao, *The lag-time approach improved drug-outcome association estimates in presence of*  
32 *protopathic bias*. *J Clin Epidemiol*, 2016. **78**: p. 101-107.
- 33 35. Saczkowski, R., et al., *Extracorporeal life support rewarming rate is associated with survival with good*  
34 *neurological outcome in accidental hypothermia*. *Eur J Cardiothorac Surg*, 2021. **59**(3): p. 593-600.
- 35 36. Filion, K.B., et al., *Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events:*  
36 *multi-database retrospective cohort study*. *Bmj*, 2020. **370**: p. m3342.
- 37 37. Joy, P.S., G. Kumar, and B. Olshansky, *Syncope: Outcomes and Conditions Associated with Hospitalization*. *Am J*  
38 *Med*, 2017. **130**(6): p. 699-706.e6.
- 39 38. Thijs, R.D., et al., *Recommendations for tilt table testing and other provocative cardiovascular autonomic tests*  
40 *in conditions that may cause transient loss of consciousness : Consensus statement of the European Federation*  
41 *of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy*  
42 *of Neurology (EAN)*. *Clin Auton Res*, 2021. **31**(3): p. 369-384.

- 1 39. Barón-Esquivias, G., et al., *Head-up tilt test diagnostic yield in syncope diagnosis*. J Electrocardiol, 2020. **63**: p.  
2 46-50.
- 3 40. Nakagaito, M., et al., *Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure*  
4 *Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus*. Circ Rep, 2019. **1**(10): p.  
5 405-413.
- 6 41. Shao, S.C., et al., *Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment:*  
7 *effect modification by atherosclerotic cardiovascular disease*. Cardiovasc Diabetol, 2021. **20**(1): p. 213.
- 8 42. Zelniker, T.A. and E. Braunwald, *Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in*  
9 *Diabetes: JACC State-of-the-Art Review*. J Am Coll Cardiol, 2018. **72**(15): p. 1845-1855.
- 10 43. McGuire, D.K., et al., *Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With*  
11 *Type 2 Diabetes: A Meta-analysis*. JAMA Cardiol, 2021. **6**(2): p. 148-158.
- 12 44. Packer, M., *Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2*  
13 *Inhibitors Reduce the Risk of Heart Failure Events*. Circulation, 2019. **140**(6): p. 443-445.
- 14 45. Hatoum, T. and R.S. Sheldon, *Syncope and the aging patient: Navigating the challenges*. Auton Neurosci, 2022.  
15 **237**: p. 102919.
- 16 46. List, J.F., et al., *Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes*. Diabetes Care, 2009.  
17 **32**(4): p. 650-7.
- 18 47. Hooshiar, S.H., *Exercise, Advanced Glycation End Products, and Their Effects on Cardiovascular Disorders: A*  
19 *Narrative Review*. Heart and Mind, (2022.6(3)): p. 139-150.
- 20 48. Zhou, J., et al., *Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl*  
21 *peptidase-4 inhibitor users*. ESC Heart Fail, 2022. **9**(2): p. 1388-1399.
- 22 49. Zelniker, T.A., et al., *SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal*  
23 *outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials*. Lancet,  
24 2019. **393**(10166): p. 31-39.
- 25 50. Lee, S., et al., *Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on*  
26 *the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched*  
27 *Study in Hong Kong*. Cardiovasc Drugs Ther, 2023. **37**(3): p. 561-569.
- 28 51. Massicotte-Azarniouch, D., et al., *The Association of Kidney Function and Albuminuria With the Risk and*  
29 *Outcomes of Syncope: A Population-Based Cohort Study*. Can J Cardiol, 2018. **34**(12): p. 1631-1640.
- 30 52. Numé, A.K., et al., *Syncope and Motor Vehicle Crash Risk: A Danish Nationwide Study*. JAMA Intern Med, 2016.  
31 **176**(4): p. 503-10.
- 32 53. Numé, A.K., et al., *Syncope and Its Impact on Occupational Accidents and Employment: A Danish Nationwide*  
33 *Retrospective Cohort Study*. Circ Cardiovasc Qual Outcomes, 2017. **10**(4).
- 34

## Figure Legends

### Structured graphical abstract

CI: confidence interval; DPP4i: dipeptidyl peptidase-4 inhibitor; HR: hazard ratio; SGLT2i: sodium-glucose cotransporter-2 inhibitor.

**Figure 1.** Flowchart of data processing.


DPP4i: dipeptidyl peptidase-4 inhibitor; IR: incidence rate; LQTS: long QT interval syndrome; SCD: sudden cardiac death; SGLT2i: sodium-glucose cotransporter-2 inhibitor; VF: ventricular fibrillation; VT: ventricular tachycardia.

**Figure 2.** Cumulative incidence curves for new-onset syncope stratified by drug exposure effects of SGLT2i and DPP4i before (A) and after (B) matching (1:1).

DPP4i: dipeptidyl peptidase-4 inhibitor; SGLT2i: sodium-glucose cotransporter-2 inhibitor.

**Figure 3.** Subgroup analysis for new-onset syncope stratified by drug exposure effects of SGLT2i versus DPP4i in the matched cohort (1:1).

ACEI: angiotensin-converting enzyme inhibitor; AMI: acute myocardial infarction; ARB: angiotensin receptor blocker; CI: confidence interval; IHD: ischemic heart disease; TIA: transient ischemic attack.



Type 2 diabetes patients with SGLT2i/DPP4i exposure from January 1st, 2015 to December 31st, 2020 in Hong Kong (N=76147)

**Patients being excluded:**

- With less than one month SGLT2i/DPP4i exposure (N=3225)
- With both SGLT2i and DPP4i use (N=15276)
- With prior VT/VF/SCD/syncope/congenital LQTS (N=2128)
- Less than 18 years old (N=148)

**Included cohort (N=55370)**  
**SGLT2i: 18751 (33.9%) vs. DPP4i: 36619 (66.1%)**  
• Male: 50.5%  
• Age: 63.2 ±12.8 years

Propensity score matching (1:1)

**Matched cohort (N=37502)**  
**SGLT2i: 18751 vs. DPP4i: 18751**  
• Male: 53.3%  
• Age: 58.9 ± 11.3 years

**SGLT2i users**

- Dapagliflozin: 10549 (56.3%)
- Empagliflozin: 3913 (20.9%)
- Canagliflozin: 4998 (26.7%)
- Ertugliflozin: 2509 (13.4%)


Follow up: 5.6 (5.2, 5.8) years

New-onset syncope: N=1374 (IR: 2.5%)  
Cardiovascular mortality: N=1762 (IR: 3.2%)  
All-cause mortality: N=6000 (IR: 10.8%)



**A**

New-onset syncope




Number at risk

DPP4i	36619	36268	35464	34049	32202	30653	166
SGLT2i	18751	18681	18592	18477	18312	18097	99

Cumulative incidence curve by drug use before matching

**B**

New-onset syncope



Number at risk

DPP4i	18751	18621	18369	17937	17286	16765	71
SGLT2i	18751	18681	18592	18477	18312	18097	99

Cumulative incidence curve by drug use after matching

**Subgroup**

**Hazard ratio (95% CI)**

**Age**

<65



0.59 [0.47-0.73]

≥65



0.71 [0.58-0.87]

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.04.23292207>; this version posted July 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

**Gender**

Male



0.66 [0.55-0.80]

Female



0.54 [0.42-0.70]


**Prior comorbidities**

Cancer (No)



0.44 [0.38-0.50]

Cancer (Yes)



0.18 [0.06-0.53]

Hypertension (No)



0.38 [0.32-0.45]

Hypertension (Yes)



0.54 [0.43-0.69]

IHD without AMI (No)



0.42 [0.36-0.49]

IHD without AMI (Yes)



0.43 [0.30-0.60]

Stroke/TIA (No)



0.42 [0.36-0.49]

Stroke/TIA (Yes)



0.55 [0.32-0.96]

Liver diseases (No)



0.43 [0.37-0.50]

Liver diseases (Yes)




0.41 [0.21-0.79]

Renal diseases (No)



0.43 [0.37-0.50]

Renal diseases (Yes)




0.12 [0.02-0.96]

Heart failure (No)



0.41 [0.35-0.47]

Heart failure (Yes)



1.12 [0.57-2.17]

AMI (No)



0.41 [0.36-0.48]

AMI (Yes)




1.32 [0.59-2.98]

Atrial fibrillation (No)



0.41 [0.36-0.48]

Atrial fibrillation (Yes)



0.86 [0.47-1.57]

**Medication use**

Insulin (No)



0.35 [0.28-0.44]

Insulin (Yes)



0.50 [0.42-0.59]

Metformin (No)



0.34 [0.19-0.61]

Metformin (Yes)




0.43 [0.38-0.50]

Sulphonylurea (No)



0.28 [0.21-0.38]

Sulphonylurea (Yes)




0.49 [0.42-0.58]

Thiozolidinedone (No)



0.40 [0.34-0.47]

Thiozolidinedone (Yes)




0.77 [0.54-1.09]

Beta-blockers (No)



0.44 [0.37-0.52]

Beta-blockers (Yes)



0.39 [0.31-0.50]

ACEI/ARB (No)



0.52 [0.39-0.68]

ACEI/ARB (Yes)



0.37 [0.31-0.44]

Anticoagulants (No)



0.42 [0.36-0.49]

Anticoagulants (Yes)



0.43 [0.30-0.63]

Antiplatelets (No)



0.39 [0.32-0.48]

Antiplatelets (Yes)



0.43 [0.35-0.52]

Lipid-lowering drugs (No)



0.36 [0.27-0.47]

Lipid-lowering drugs (Yes)



0.44 [0.37-0.52]

0.2 0.4 0.6 0.8 1 1.2 1.4

Favour SGLT2i

Favour DPP4i